← Back to Search

Senolytic Agent

Senolytic Therapy for Chronic Kidney Disease

Phase 2

Waitlist Available

Led By LaTonya J Hickson, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Chronic kidney disease estimated glomerular filtration rate (eGFR) 15-45 ml/min/1.73m2

Diabetes mellitus and taking diabetes medications

Must not have

New invasive cancer except non-melanoma skin cancers

Inability to tolerate oral medications

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, day 14, month 4, month 12

Awards & highlights

Summary

This trial will test whether getting rid of senescent cells can help people with chronic kidney disease by reducing senescence burden, improving physical ability or frailty, and increasing mesenchymal stem cell functionality.

Who is the study for?

This trial is for adults aged 40-80 with chronic kidney disease (eGFR 15-45 ml/min/1.73m2) and diabetes on medication. Excluded are those with recent substance abuse, HIV, hepatitis B/C, pregnancy, certain heart conditions or allergies to the drugs tested, among other criteria.

What is being tested?

The study tests whether Dasatinib and Quercetin can reduce aging cells in patients with chronic kidney disease to improve physical function and stem cell health. Participants will be grouped to receive either drug combination.

What are the potential side effects?

Potential side effects of Dasatinib and Quercetin may include changes in blood counts leading to increased risk of infections or bleeding, nausea, diarrhea, muscle cramps, fatigue, fluid retention around the heart or lungs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney function is reduced, with an eGFR between 15-45.

Select...

I have diabetes and am on medication for it.

Select...

I am between 40 and 80 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a new cancer diagnosis that is not a non-melanoma skin cancer.

Select...

I cannot take medications by mouth.

Select...

I am currently on medication to suppress my immune system.

Select...

My weight is over 150 kg or my BMI is over 50.

Select...

I am not willing to stop my acid reflux medication for 3 weeks.

Select...

My lupus is not under control.

Select...

I have unmanaged fluid buildup in my chest or abdomen.

Select...

I am HIV positive.

Select...

I am unable to understand and give consent for treatment.

Select...

I am on a medication that targets cancer growth.

Select...

I have taken quinolone antibiotics in the last 10 days.

Select...

I am taking medication that strongly affects liver enzyme CYP3A4.

Select...

I do not have an active hepatitis B or C infection.

Select...

I have a kidney condition called glomerulonephritis.

Select...

I have an invasive fungal or viral infection.

Select...

I have been diagnosed with kidney artery disease.

Select...

I have a genetic form of polycystic kidney disease.

Select...

I have been diagnosed with nephrotic syndrome.

Select...

I have had a solid organ transplant.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, day 14, month 4, month 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, day 14, month 4, month 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 14, month 4, month 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in proportion of senescent cells (representing the total senescent cell burden) present

Secondary study objectives

Change in Frailty index score

Change in kidney function

Change in mesenchymal stem cell function

+1 more

Trial Design

2Treatment groups

Active Control

Group I: Group 1: ObservationalActive Control1 Intervention

Observational Only

Group II: Group 2: Dasatinib & QuercetinActive Control2 Interventions

The drugs dasatinib and quercetin will be used in this arm

0 / 22Eligibility criteria met

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,298 Previous Clinical Trials

3,958,415 Total Patients Enrolled

LaTonya J Hickson, MDPrincipal InvestigatorMayo Clinic

2 Previous Clinical Trials

32 Total Patients Enrolled

Media Library

Dasatinib (Senolytic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT02848131 — Phase 2

Dasatinib (Senolytic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02848131 — Phase 2

Chronic Kidney Disease Clinical Trial 2023: Dasatinib Highlights & Side Effects. Trial Name: NCT02848131 — Phase 2

Chronic Kidney Disease Research Study Groups: Group 1: Observational, Group 2: Dasatinib & Quercetin

~2 spots leftby Apr 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.